A Living Biobank Of Ovarian Cancer – A Model For Drug Discovery
Synthetic lethality is a circumstance in which a drug is selectively
deadly to cancer cells due to the mutations and genetic changes that have
occurred during oncogenesis and progression. Oftentimes a cancer will lose redundancy,
that is it will jettison certain survival/...
A Living Biobank Of Non-Small Cell Lung Cancer Organoids
Globally, cancer of the lung is the most common cause of
cancer related mortality. It is also the most commonly diagnosed. 3D patient derived
organoids provide a more faithful model of cancer than 2D in vitro cell
culture and represent a model...
The Swedish p53 Study (SWEP53) With Biobank Option
The Swedish p53 Study (SWEP53) is a germ line TP53 pathogenic variant patient registry with three optional parts: a biobank, a surveillance program and a psychosocial evaluation of the surveillance. The full study outline was published in the journal...
The Chilean Biobanking Network – Predictive, Personalized, Preventive, Participatory
An article was recently published in the Medical Review of
Chile with senior author María Elena Cabrera of El Salvador Hospital, Santiago,
about the potential for developing a biobanking network within the country. According to the authors Chile has a unique...
The Gift Of Life Marrow Registry To Receive Advocacy Award At World Stem Cell...
The formal ceremony of the 2020 Stem Cell and Regenerative Medicine Action Awards will take place at a gala reception and dinner on January 23, during the 15th annual World Stem Cell Summit (WSCS) at the Hyatt Regency in...
Australia’s Great Barrier Reef Living Coral Biobank
As coral reefs worldwide decline due to climate change,
severe storm events and coral disease, Australian non-profit organisation GBR
Legacy, with partners Corals of the World and Cairns Marine, will safeguard the
biodiversity of all known hard coral species by creating the...
Over 250,000 Participants Now Enrolled In Geisinger’s MyCode Precision Medicine Project
Geisinger’s groundbreaking precision medicine project,
MyCode, has enrolled more than 250,000 participants in Pennsylvania and New
Jersey, reaching a major landmark in the project. With DNA sequence and health
data currently available on 145,000 of these participants, MyCode is the
largest study of...
Kazan Federal University’s Extreme Biology Lab To Biobank Endangered Bird Species
Kazan Federal University’s Extreme Biology Lab has obtained
grant funding with colleagues from Japan and Thailand. The support is provided
by the Russian Foundation for Basic Research and the Science and Innovation in
East Asia Consortium. Kazan Federal University’s partners are Mahidol
University...
ImmunoQure And Memo Therapeutics Collaborate To Biobank Rare Disease Autoantibodies
ImmunoQure AG, a biotechnology company focused on the
development of autoantibodies as therapeutics to treat human diseases and Memo
Therapeutics AG, a biotechnology company focused on the discovery and
development of therapeutic antibodies from cognate paired antibody libraries have
established a collaborative partnership...
CureDuchenne Launches Duchenne Muscular Dystrophy Biobank
CureDuchenne, a global leader in research, patient care, and
innovation in improving and extending the lives of those living with Duchenne
muscular dystrophy (Duchenne), has initiated the development of a biobank for
Duchenne in partnership with University of California, Irvine (UCI) and...
